Literature DB >> 9325072

Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls.

M Mironova1, G Virella, I Virella-Lowell, M F Lopes-Virella.   

Abstract

Antibodies to oxidized LDL (ox-LDL) and LDL-containing immune complexes (LDL-IC) have been reported to be associated with the presence or progression of arteriosclerosis. We screened for anti-modified LDL antibodies and isolated soluble IC by precipitation with 3.5% (w/v) polyethylene glycol (PEG) 6000 in two groups. The patient group was constituted by 16 insulin-dependent diabetes mellitus subjects free of macrovascular complications. The control group was constituted by 16 healthy, age-, gender-, race-, and body mass index-matched nondiabetic subjects. We detected anti-ox-LDL antibodies and anti-malondialdehyde-modified LDL antibodies with similar levels in patients and controls, while the levels of anti-glycated LDL antibodies were very low, but slightly higher in diabetics than in healthy controls. Isolated LDL-IC were adsorbed to red blood cells (RBC) and incubated with human macrophages for 18 hr at 37 degrees C. Under those experimental conditions, RBC-adsorbed IC are taken up by macrophages but the RBC remain intact and are not ingested. Slightly higher levels of cholesteryl ester (CE) accumulation were measured in macrophages incubated with RBC to which we adsorbed IC isolated from diabetics (15.4 +/- 2.5 micrograms/mg of protein, mean +/- SEM) than in macrophages incubated with IC isolated from controls (12.5 +/- 1.6 micrograms/mg of protein, mean +/- SEM), but the difference did not reach statistical significance. PEG-precipitable IC isolated from both normal and diabetic subjects led, in some instances, to the transformation of macrophages into foam cells. Significant correlations were observed between CE accumulation and the content of apo B (P < 0.0001), total cholesterol (P = 0.0004), IgG (P = 0.015), and IgA (P = 0.015) in the isolated IC. The correlation between CE accumulation and the content of apo B in isolated IC was stronger in diabetics than in the control group (r = 0.759 vs r = 0.500). Fractionation of isolated IC in immobilized protein A/G yielded immunoglobulin-rich fractions which contained cholesterol and IgG anti-ox-LDL antibodies. The cholesterol content of these fractions was significantly correlated (P = 0.001) with CE accumulation. In conclusion, both diabetics and normal individuals have circulating IC whose atherogenic potential appears to be related to the presence of LDL and antibodies of the IgG and IgA isotypes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9325072     DOI: 10.1006/clin.1997.4404

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  13 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

Review 3.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

Review 4.  Diabetes, oxidative stress and physical exercise.

Authors:  Mustafa Atalay; David E Laaksonen
Journal:  J Sports Sci Med       Date:  2002-03-04       Impact factor: 2.988

5.  High levels of oxidized LDL in circulating immune complexes are associated with increased odds of developing abnormal albuminuria in Type 1 diabetes.

Authors:  Maria F Lopes-Virella; Rickey E Carter; Nathaniel L Baker; John Lachin; Gabriel Virella
Journal:  Nephrol Dial Transplant       Date:  2011-08-19       Impact factor: 5.992

6.  Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes.

Authors:  Maria F Lopes-Virella; Nathaniel L Baker; Kelly J Hunt; John Lachin; David Nathan; G Virella
Journal:  Atherosclerosis       Date:  2010-11-17       Impact factor: 5.162

7.  LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses.

Authors:  Richard L Klein; Rickey E Carter; Alicia J Jenkins; Timothy J Lyons; Nathaniel L Baker; Gregory E Gilbert; Gabriel Virella; Maria F Lopes-Virella
Journal:  J Diabetes Complications       Date:  2010-06-03       Impact factor: 2.852

8.  Development of capture assays for different modifications of human low-density lipoprotein.

Authors:  Gabriel Virella; M Brooks Derrick; Virginia Pate; Charlyne Chassereau; Suzanne R Thorpe; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

Review 9.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

10.  Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes.

Authors:  Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; John Lachin; David M Nathan; G Virella
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.